Intrexon | XON - Interest Expense On Debt


Intrexon reported $2K in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
Agenus USD 14.67M 1.35M Mar/2026
Alaunos Therapeutics USD 1.07M 215K Jun/2023
Amgen USD 653M 94.99B Sep/2026
Anika Therapeutics 183.47M 4.09M Jun/2026
Arrowhead Research USD 24.56M 716K Jun/2026
AstraZeneca USD 371M 31M Sep/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
Gilead Sciences USD 269M 22M Sep/2026
GlaxoSmithKline GBP 219M 98M Sep/2026
Heron Therapeutics USD 600K 100K Dec/2024
Incyte USD 605K 23K Sep/2026
Intrexon USD 2K 5K Jun/2024
Karyopharm Therapeutics USD 12.55M 66K Mar/2026
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
MacroGenics USD 4.4M 493K Jun/2026
MannKind USD 10.58M 4.24M Sep/2026
Merck USD 525M 46M Jun/2026
Novartis USD 468M 6M Sep/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Thermo Fisher Scientific USD 417M 63M Sep/2026
Veracyte USD 2K 1000 Dec/2023
Xencor USD 4.11M 3.24M Sep/2026